Akari Therapeutics Plcの内部者の所有権

Akari Therapeutics Plcの内部者の所有権は何ですか。

Akari Therapeutics Plcの内部者の所有権は4.89%です。

内部者の所有権の定義は何ですか。



管理の所有権(Insider Ownership)は、発行済株式総数で除したインサイダー(5%超を所有する株主または取締役または役員) が所有する株式総数によって計算されます。

A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.

A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.

NASDAQのセクタHealth Careにおける内部者の所有権の企業と比べるAkari Therapeutics Plc

Akari Therapeutics Plcは何をしますか。

akari is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics to treat orphan autoimmune and inflammatory diseases. akari’s lead drug, coversin, a second-generation and potentially best-in-class complement inhibitor, acts on complement component-c5, preventing release of c5a and formation of c5b – 9 (also known as the membrane attack complex or mac). coversin is a recombinant small protein (16,740 da) derived from a native protein discovered in the saliva of the ornithodoros moubata tick, where it modulates the host immune system to allow the parasite to feed without alerting the host to its presence or provoking an immune response.

Akari Therapeutics Plcと類似の内部者の所有権